Retatrutide 5mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Retatrutide is a fatty acid acylated single peptide combining GCGR, GIPR and GLP-1R activity on a heavily modified GIP backbone, with albumin binding giving it a half-life long enough for once-weekly administration in published protocols. This 5mg vial is the smallest retatrutide presentation offered and is intended for pilot experiments, receptor-binding assays and low-concentration arms of dose-response studies, where a larger vial would leave reconstituted material sitting past its usable window.
Frequently Bought Together
Retatrutide 5mg
5mg
$59 USD
Bundle & Save
$159 USD
Save $9 USD
$224 USD
Save $24 USD
$269 USD
Save $39 USD
$369 USD
Save $74 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.